EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Blood Cell Biomarkers of Inflammation and Cytokine Levels as Predictors of Response to Biologics in Patients with Psoriasis

Clara Sophie Bramsen Andersen, Amanda Kvist-Hansen iD, Mie Siewertsen, Christian Enevold, Peter Riis Hansen iD, Diljit Kaur-Knudsen, Claus Zachariae iD, Claus Henrik Nielsen iD, Nikolai Loft iD, Lone Skov iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24076111 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Clara Sophie Bramsen Andersen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen University Hospital, 2900 Hellerup, Denmark. Hauptthemen laut MEDLINE: Biological Products, Psoriasis. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Aage Bang Foundation, Ebba Celinders Legat, AP Møller Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

For people with psoriasis, biomarkers aiding in the personalization of treatment with biologics are needed. We examined the usefulness of several biomarkers of inflammation in this respect. The neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), and the systemic immune–inflammation index (SII) were measured in patients with psoriasis initiating TNF-α inhibitors (n = 131), IL-17/IL-17R inhibitors (n = 65), or IL-23/IL-12/23 inhibitors (n = 50). The blood levels of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, interferon (IFN)-γ, IL-17A, IL-6, soluble IL-6 receptor (sIL-6R), and soluble IL-6 signal transducer (sIL-6ST) were measured in patients initiating adalimumab (n = 62) or IL-17/IL-17R inhibitors (n = 24). Treatment response was defined by a psoriasis area and severity index (PASI) ≤ 2 three months after treatment initiation. Responders to TNF-α inhibitors had a lower NLR at baseline than non-responders (median and interquartile range (IQR) 2.15 (1.67–2.86) vs. 2.54 (1.88–3.55); p = 0.04). Responders to treatment with adalimumab had lower IL-6 levels at baseline than non-responders (0.99 (0.42–1.4) vs. 1.62 (0.96–2.41) pg/mL; p = 0.02). For the majority of patients, the IL-17A, IL-1β, and IFN-γ levels were below quantification limits. NLR and IL-6 may serve as predictive biomarkers of treatment response to TNF-α inhibitor therapy in patients with psoriasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biological ProductsPsoriasisHumansInterleukin-17AdalimumabCytokinesTumor Necrosis Factor-alphaInterleukin-6BiomarkersBlood CellsInflammation

Stichwörter der Autor:innen

biologicsblood cytokinesneutrophil-to-lymphocyte ratiopredictive biomarkerspsoriasisresponse to treatment

Substanzen

Interleukin-17AdalimumabCytokinesTumor Necrosis Factor-alphaBiological ProductsInterleukin-6Biomarkers

Autor:innen und Institutionen

  • Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen University Hospital, 2900 Hellerup, Denmark.
  • Institute for Inflammation Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen University Hospital, 2200 Copenhagen, Denmark.
  • Department of Cardiology, Herlev and Gentofte Hospital, Copenhagen University Hospital, 2900 Hellerup, Denmark.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
  • Department of Odontology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.

ORCID-Profile: Amanda Kvist-Hansen, Peter Riis Hansen, Claus Zachariae, Claus Henrik Nielsen, Nikolai Loft, Lone Skov

Förderung

  • Aage Bang Foundation
  • Ebba Celinders Legat
  • AP Møller Foundation
  • The Danish Psoriasis Foundation
  • LEO Foundation
  • Kong Christian X Foundation
  • the Aage Bangs Fond
  • the Kong Christian X fond

Zitieren

APA

Andersen, C. S. B., Kvist-Hansen, A., Siewertsen, M., Enevold, C., Hansen, P. R., Kaur-Knudsen, D., Zachariae, C., Nielsen, C. H., Loft, N., & Skov, L. (2023). Blood Cell Biomarkers of Inflammation and Cytokine Levels as Predictors of Response to Biologics in Patients with Psoriasis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24076111

Vancouver

Andersen CSB, Kvist-Hansen A, Siewertsen M, Enevold C, Hansen PR, Kaur-Knudsen D, et al. Blood Cell Biomarkers of Inflammation and Cytokine Levels as Predictors of Response to Biologics in Patients with Psoriasis. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24076111

BibTeX
@article{Andersen2023,
  author = {Andersen, Clara Sophie Bramsen and Kvist-Hansen, Amanda and Siewertsen, Mie and Enevold, Christian and Hansen, Peter Riis and Kaur-Knudsen, Diljit and Zachariae, Claus and Nielsen, Claus Henrik and Loft, Nikolai and Skov, Lone},
  title = {Blood Cell Biomarkers of Inflammation and Cytokine Levels as Predictors of Response to Biologics in Patients with Psoriasis},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24076111}
}
Kostenlos starten →